# Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

> **NCT01276496** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Estrogen Receptor Negative
- HER2/Neu Negative
- Male Breast Carcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Cilengitide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01276496
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-03
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276496, "Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01276496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*